Cambridge Healthtech Institute’s Inaugural

Quantitative Immune Profiling and Immune Monitoring

August 28-29, 2017 | Sheraton Boston | Boston, MA

Advances in immuno-oncology promise to revolutionize cancer treatment. However, many patients do not respond to immunotherapy. Immune profiling promises to identify biomarkers that predict response to immunotherapy and to help monitor its progress. Cambridge Healthtech Institute’s Inaugural Quantitative Immune Profiling and Immune Monitoring meeting will cover quantitative approaches to assess the state of the immune system, profile the tumor microenvironment and peripheral blood, determine tumor mutational burden and profile neoepitopes, and develop predictive and response biomarkers.

Preliminary Agenda


IMMUNE MONITORING: BIOMARKERS OF RESPONSE TO IMMUNOTHERAPY

Cancer Immunotherapy Trials Network (CITN): Immune Monitoring Analysis of Multicenter Trials

Steven Fling, Ph.D., Staff Scientist, Vaccine & Infectious Disease, Fred Hutchinson Cancer Research Center; Director, Cancer Immunotherapy Trials Network Immune Monitoring Laboratory

Biomarkers for Cancer Immunotherapy Selection and Monitoring: Derived from Tissue, Blood, and Other Biospecimens

Glen J. Weiss, M.D., MBA, Director of Clinical Research and Phase I & II Clinical Trials at Cancer Treatment Centers of America, Goodyear, AZ


IMMUNOPHENOTYPING: BIOMARKER DISCOVERY AND VALIDATION FOR IMMUNO-ONCOLOGY

The New Precision Medicine: The Role of Dynamic Tumor and Immune Sampling in Immunotherapy

Morganna Freeman, DO, FACP, Associate Director, Melanoma & Cutaneous Oncology Program, The Angeles Clinic and Research Institute

In situ Multiparametric Tumor Immunoprofiling for Translational Research in Oncology

Kurt Schalper, M.D., Ph.D., Assistant Professor, Pathology and Medicine (Medical Oncology), Yale School of Medicine

Intersection of Host Factors and Novel Biomarkers for Immunotherapy

Adil Daud, M.D., Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center


IMMUNOSEQUENCING AND IMMUNE CELL INFILTRATION PROFILING

Density, Distribution and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma

Michael T. Tetzlaff, M.D., Ph.D., Assistant Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center

Applying Next-Generation Sequencing to Assess Immune-Mediated Drug Hypersensitivity

Masahide Yano, Ph.D., Research Scientist, Center for Drug Evaluation and Research, FDA


PROFILING THE TUMOR MICROENVIRONMENT

Profiling B Cell Subtypes and Autoantibodies for Immune Monitoring

Sam Hanash, M.D., Ph.D., McCombs Institute for Cancer Early Detection and Treatment, MD Anderson Cancer Center

Expression Profiling and Immunohistochemistry to Identify Cancer Immune Landscapes

Darrell R. Borger, Ph.D., Co-Director, Translational Research Laboratory, and Director, Biomarker Laboratory, Massachusetts General Hospital and Harvard Medical School

Major Histocompatibility Class II on Tumor Cells: Regulation, Functionality, and Predictive Role in PD-1/L1-Targeted Therapy Outcomes

Justin Balko, Pharm.D., Ph.D., Assistant Professor, Medicine & Cancer Biology, Vanderbilt University School of Medicine; Leader of Molecular Oncology, Center for Cancer-Targeted Therapies, Vanderbilt Ingram Cancer Center




For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
juliab@healthtech.com

For exhibit & sponsorship opportunities, please contact:


Rod Eymael
Manager, Business Development
781-247-6286
reymael@healthtech.com

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today